Sunday, November 04, 2012

ALTITUDE Autopsy Shows What Went Wrong With Aliskiren « CardioBrief

The authors concluded that the addition of aliskiren to standard therapy in high risk type 2 diabetics “is not supported by these data and may even be harmful.” The result of ALTITUDE, they write, “underscores the need to go beyond surrogate biomarkers and obtain risk-benefit data from clinical end-point trials to better inform clinical decisions.”

No comments: